Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 439459

Next Previous
Drug Profile

SAR 439459

Alternative Names: Anti-TGFb SAR-439459; Anti-transforming Growth Factor-beta mAb SAR439459; SAR-439459

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Discontinued Osteogenesis imperfecta; Solid tumours

Most Recent Events

  • 31 Dec 2024 Discontinued - Phase-I for Osteogenesis imperfecta in France, Canada, Australia and USA (IV)
  • 12 Nov 2024 Sanofi terminates phase-I clinical trials in Osteogenesis imperfecta in USA, France, Canada, Australia (IV) due tosponsor decision to prematurely stop the study (NCT05231668)
  • 23 Feb 2024 SAR 439459 receives Orphan Drug status for Osteogenesis imperfecta in USA prior to February 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top